239 related articles for article (PubMed ID: 35314545)
1. Nivolumab-induced Myositis and Myocarditis with Positive Anti-titin Antibody and Anti-voltage-gated Potassium Channel Kv1.4 Antibody.
Ono R; Iwai Y; Yamazaki T; Takahashi H; Hori Y; Fukushima K; Saotome T
Intern Med; 2022 Oct; 61(19):2973-2979. PubMed ID: 35314545
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
[TBL] [Abstract][Full Text] [Related]
3. Anti-Kv1.4 Antibody-positive Nivolumab-induced Myasthenia Gravis and Myositis Presenting with Bilateral Ptosis and Demonstrating Different Pathophysiologies.
Kitazaki Y; Yamamura O; Usui K; Ueno A; Sanada S; Sasaki H; Endo Y; Enomoto S; Ikawa M; Nakamoto Y; Hamano T
Intern Med; 2023; 62(20):3013-3020. PubMed ID: 37839874
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies.
Fazal M; Prentice DA; Kho LK; Fysh E
Intern Med J; 2020 Aug; 50(8):1003-1006. PubMed ID: 33306231
[TBL] [Abstract][Full Text] [Related]
5. Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and/or myocarditis.
Kufukihara K; Watanabe Y; Inagaki T; Takamatsu K; Nakane S; Nakahara J; Ando Y; Suzuki S
Sci Rep; 2019 Mar; 9(1):5284. PubMed ID: 30918333
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
Suzuki S; Ishikawa N; Konoeda F; Seki N; Fukushima S; Takahashi K; Uhara H; Hasegawa Y; Inomata S; Otani Y; Yokota K; Hirose T; Tanaka R; Suzuki N; Matsui M
Neurology; 2017 Sep; 89(11):1127-1134. PubMed ID: 28821685
[TBL] [Abstract][Full Text] [Related]
7. [Immune checkpoint inhibitor-induced anti-striational antibodies in myasthenia gravis and myositis: a case report].
Sugiyama Y; Esa Y; Watanabe A; Kobayashi J; Suzuki S; Takahashi D
Rinsho Shinkeigaku; 2021 Sep; 61(9):630-634. PubMed ID: 34433744
[TBL] [Abstract][Full Text] [Related]
8. Classification of myasthenia gravis based on autoantibody status.
Suzuki S; Utsugisawa K; Nagane Y; Satoh T; Terayama Y; Suzuki N; Kuwana M
Arch Neurol; 2007 Aug; 64(8):1121-4. PubMed ID: 17698702
[TBL] [Abstract][Full Text] [Related]
9. [A case of anti-titin antibody positive nivolumab-related necrotizing myopathy with myasthenia gravis].
Isami A; Uchiyama A; Shimaoka Y; Suzuki S; Kawachi I; Fujita N
Rinsho Shinkeigaku; 2019 Jul; 59(7):431-435. PubMed ID: 31243249
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis.
Wang C; Zeng H; Fang W; Song L
Invest New Drugs; 2023 Apr; 41(2):333-339. PubMed ID: 36988830
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia.
Mygland A; Vincent A; Newsom-Davis J; Kaminski H; Zorzato F; Agius M; Gilhus NE; Aarli JA
Arch Neurol; 2000 Apr; 57(4):527-31. PubMed ID: 10768628
[TBL] [Abstract][Full Text] [Related]
12. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review.
Chen JH; Lee KY; Hu CJ; Chung CC
Medicine (Baltimore); 2017 Dec; 96(50):e9262. PubMed ID: 29390370
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings-A Case Report and Literature Review.
Giovannini E; Bonasoni MP; D'Aleo M; Tamagnini I; Tudini M; Fais P; Pelotti S
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446095
[TBL] [Abstract][Full Text] [Related]
14. Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report.
Cham J; Ng D; Nicholson L
J Med Case Rep; 2021 May; 15(1):278. PubMed ID: 34053457
[TBL] [Abstract][Full Text] [Related]
15. Asymptomatic Myocarditis with Mild Cardiac Marker Elevation Following Nivolumab-Induced Myositis.
Shindo A; Yamasaki M; Uchino K; Yamasaki M
Int Heart J; 2022; 63(1):180-183. PubMed ID: 35095069
[TBL] [Abstract][Full Text] [Related]
16. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.
Pathak R; Katel A; Massarelli E; Villaflor VM; Sun V; Salgia R
Oncologist; 2021 Dec; 26(12):1052-1061. PubMed ID: 34378270
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome.
Lipe DN; Galvis-Carvajal E; Rajha E; Wechsler AH; Gaeta S
Am J Emerg Med; 2021 Aug; 46():51-55. PubMed ID: 33721590
[TBL] [Abstract][Full Text] [Related]
19. Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series.
Weaver JM; Dodd K; Knight T; Chaudhri M; Khera R; Lilleker JB; Roberts M; Lorigan P; Cooksley T
Support Care Cancer; 2023 Aug; 31(9):518. PubMed ID: 37572133
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: a case report.
Saishu Y; Yoshida T; Seino Y; Nomura T
J Med Case Rep; 2022 Feb; 16(1):61. PubMed ID: 35152911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]